Huntington's Disease

Securities class action filed against $QURE for alleged misrepresentation regarding Pivotal Study design and FDA approval timeline for Huntington's disease treatment.

$QURE plummeted 49% after FDA feedback on AMT-130 gene therapy. Pomerantz Law Firm filed class action lawsuit; investor deadline April 13, 2026.

uniQure shares collapsed 49% after FDA signaled Phase I/II data insufficient for AMT-130 approval, prompting investors to file class action lawsuit.

Rosen Law Firm urges $QURE investors to join securities lawsuit alleging misrepresentation of Pivotal Study design and BLA timeline delays. Lead plaintiff deadline: April 13, 2026.

Securities class action filed against uniQure alleging FDA approval misrepresentations. April 13, 2026 deadline for lead plaintiff claims.

Kessler Topaz files class action against $QURE over alleged misleading statements about AMT-130 FDA approval timeline, following 49% stock plunge in November 2025.

Class action lawsuit filed against $QURE over alleged misstatements about Huntington's disease therapy approval timeline. Stock crashed 49% after FDA stance shift.

uniQure faces securities lawsuit for allegedly misrepresenting Huntington's study design approval and downplaying BLA delays. Investors must act by April 13, 2026.

Class action lawsuit filed against $QURE over alleged misstatements about AMT-130 gene therapy FDA approval status. Stock plunged 49% after FDA reversed position on Phase I/II data adequacy.

uniQure's $QURE stock crashes 49% after FDA rejects Huntington's gene therapy approval pathway; securities fraud lawsuit filed alleging misleading statements about regulatory expectations.

uniQure faces securities class action over alleged misrepresentations regarding FDA approval status of Huntington's Disease trial design and regulatory timeline delays. Lead plaintiff deadline April 13, 2026.

UniQure faces securities lawsuit alleging material misrepresentations about its Huntington's Disease trial design and FDA approval status. Lead plaintiff deadline is April 13, 2026.

uniQure faces securities class action over allegedly misleading FDA approval claims and timeline delays. Investors must act before April 13, 2026 deadline.

UniQure faces class action lawsuit over alleged FDA disclosure misrepresentations. Investors have until April 13, 2026 deadline to join litigation.

Law firm sues uniQure for allegedly misrepresenting gene therapy trial status and FDA approval timeline, causing stock to surge 250% then fall 49% after FDA reversal.

Rosen Law Firm sued uniQure for allegedly misleading investors about FDA approval timelines and regulatory study status between September-October 2025.